Patents by Inventor Daniel T. MacLeod

Daniel T. MacLeod has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ENGINEERED MEGANUCLEASES WITH RECOGNITION SEQUENCES FOUND IN THE HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180289741
    Abstract: Disclosed herein are recombinant meganucleases engineered to recognize and cleave a recognition sequence present in the human T cell receptor alpha constant region gene. The present disclosure further relates to the use of such recombinant meganucleases in methods for producing genetically-modified eukaryotic cells.
    Type: Application
    Filed: October 5, 2016
    Publication date: October 11, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Michael G. Nicholson, James Jefferson Smith, Derek Jantz, Victor Bartsevich, Daniel T. MacLeod, Jeyaraj Antony
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 10093899
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 9, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 10093900
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: October 9, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180265845
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 20, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180258392
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: April 27, 2018
    Publication date: September 13, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9993501
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 12, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9993502
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: June 12, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180140635
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 24, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20180133254
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: January 8, 2018
    Publication date: May 17, 2018
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9969975
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: May 15, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9950011
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 24, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9950010
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: January 8, 2018
    Date of Patent: April 24, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Jeyaraj Antony, Victor Bartsevich
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9889161
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 13, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony
  • Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene
    Patent number: 9889160
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Grant
    Filed: May 26, 2017
    Date of Patent: February 13, 2018
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20170333481
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 23, 2017
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony
  • GENETICALLY-MODIFIED CELLS COMPRISING A MODIFIED HUMAN T CELL RECEPTOR ALPHA CONSTANT REGION GENE
    Publication number: 20170335010
    Abstract: Disclosed herein is a genetically-modified cell comprising in its genome a modified human T cell receptor alpha constant region gene, wherein the cell has reduced cell-surface expression of the endogenous T cell receptor. The present disclosure further relates to methods for producing such a genetically-modified cell, and to methods of using such a cell for treating a disease in a subject.
    Type: Application
    Filed: May 26, 2017
    Publication date: November 23, 2017
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Michael G. Nicholson, Daniel T. MacLeod, Victor Bartsevich, Jeyaraj Antony